I 

109TH CONGRESS 

1ST SESSION H. R. 2574 

To amend the Public Health Service Act to provide for a program at the 

National Institutes of Health to conduct and support research on animals 

to develop techniques for the derivation of stem cells from embryos 

that do not harm the embryos, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 24, 2005 

Mr. BARTLETT of Maryland (for himself, Mr. GINGREY, Mr. NORWOOD, Mr. 

OSBORNE, Mr. CULBERSON, Mr. ENGLISH of Pennsylvania, Mr. ROHRABACHER, Mr. PRICE of Georgia, and Mr. CANNON) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to provide for 

a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos 

that do not harm the embryos, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Respect for Life Em5 bryonic Stem Cell Act of 2005’’. 
2 

•HR 2574 IH 

1 SEC. 2. FINDINGS. 

2 The Congress finds as follows: 

3 (1) The President’s Council on Bioethics in its 

4 May 2005 White Paper: ‘‘Alternative Sources of 

5 Pluripotent Stem Cells,’’ acknowledges that 

6 pluripotent stem cell lines might be derived from an 

7 early stage human embryo without harming the em8 bryo’s prospects for developing into a baby. 

9 (2) Identical twinning occurs spontaneously in 

10 nature during at least two stages of the in vivo 

11 human development process demonstrating the via12 bility and feasibility of the removal of some cells 

13 from an early stage human embryo without harming 

14 the embryo’s ability to develop into a baby. 

15 (3) The removal of some cells from living 

16 human embryos is already occurring to conduct 

17 preimplantation genetic diagnosis (‘‘PGD’’). PGD is 

18 a procedure increasingly offered to individuals seek19 ing to become parents as an option in conjunction 

20 with assisted reproductive technologies to diagnose 

21 their embryos created through in vitro fertilization 

22 (‘‘IVF’’) for genetic and chromosomal abnormalities 

23 prior to implantation and pregnancy. 

24 (4) There have been reports that more than 

25 1,000 babies have been born worldwide and more 
3 

•HR 2574 IH 

1 than 150 babies have been born in the United States 

2 after undergoing PGD as early stage embryos. 

3 (5) IVF to create and PGD to diagnose early 

4 stage human embryos is proceeding without Federal 

5 funding. 

6 (6) There is no Federal prohibition against 

7 using IVF to create or PGD to diagnose early stage 

8 human embryos. 

9 (7) Informed parental consent is obtained and 

10 granted by individuals to utilize IVF and PGD on 

11 behalf of themselves and to benefit their children. 

12 (8) Cells removed for PGD from an early stage 

13 human embryo might be cultured to produce and 

14 store a stock of cells that could become a genetically 

15 matched repair kit for that individual. 

16 (9) Surplus cells from an individual’s repair kit 

17 might be used to establish an embryonic stem cell 

18 line made available for basic and applied research to 

19 develop treatments for debilitating and deadly 

20 human ailments. 

21 (10) Individuals seeking to become parents who 

22 have already chosen and committed to use PGD and 

23 establish a repair kit for the benefit of their children 

24 could have the option to donate surplus cells from 
4 

•HR 2574 IH 

1 their children’s repair kit for the establishment of a 

2 new embryonic stem cell line. 

3 SEC. 3. DERIVATION OF STEM CELLS WITHOUT HARMING 

4 EMBRYOS; ANIMAL RESEARCH THROUGH NA5 TIONAL INSTITUTES OF HEALTH. 

6 Part B of title IV of the Public Health Service Act 

7 (42 U.S.C 284) is amended by adding at the end the fol8 lowing: 

9 ‘‘SEC. 409J. BASIC AND APPLIED RESEARCH ON DERIVA10 TION OF STEM CELLS WITHOUT HARMING 

11 EMBRYOS. 

12 ‘‘(a) IN GENERAL.—With respect to producing stem 

13 cell lines for research on treatments for diseases and other 

14 adverse health conditions, the Director of NIH shall, 

15 through the appropriate national research institutes, pro16 vide for the conduct and support of basic and applied re17 search— 

18 ‘‘(1) to develop techniques for the derivation of 

19 stem cells from embryos that do not harm the em20 bryos; and 

21 ‘‘(2) in the case of stem cells that are derived 

22 without harming the embryo, to develop techniques 

23 for storing the stem cells for the possibility that in 

24 the future a therapy may be developed that uses the 
5 

•HR 2574 IH 

1 stem cells of an animal to adapt the therapy to that 

2 particular animal. 

3 ‘‘(b) PROHIBITIONS REGARDING CLINICAL RE4 SEARCH.—Research under subsection (a) may not include 

5 clinical research, and may not include any research that— 

6 ‘‘(1) involves the derivation of stem cells from 

7 human embryos; or 

8 ‘‘(2) uses any stem cell to create or to attempt 

9 to create a human embryo. 

10 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 

11 purpose of carrying out this section, there is authorized 

12 to be appropriated $10,000,000 in the aggregate for the 

13 fiscal years 2006 through 2010.’’. 

Æ